Thiazolidinediones and slowing the progression of diabetes.
A continuing goal of treatment of diabetes is to slow the progression of the disease through the preservation of beta-cell function. To assess efficacious and cost-effective methods of doing this, The Pharmacy & Therapeutics Society (Glastonbury, CT) assembled a study group of health plan medical directors. Based on a review of the data, the group studied the value of earlier diagnosis and the administration of thiazolidinediones. The potential role for health plans to support this approach to diabetes care is outlined below.
Section of Endocrinology/Metabolism, West Virginia University, Morgantown, West Virginia, USA.
Timothy
T
Jackson
Anthony
A
Aquilina
John
J
Bloom
Humberto
H
Guerra-Garcia
Ira
I
Salom
Albert
A
Tzeel
Robert
R
Kaminsky
D003362:Cost-Benefit Analysis; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D018450:Disease Progression; D042241:Early Diagnosis; D006291:Health Policy; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism; D008329:Managed Care Programs / Q000191:economics; D011320:Primary Health Care / Q000191:economics / Q000592:standards*; D011788:Quality of Life; D045162:Thiazolidinediones / Q000191:economics / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones